Imiquimod-induced FasR-mediated apoptosis, may contribute to the effectiveness of imiquimod 5% cream for the treatment of BCC
(8). The initial study of topical imiquimod 5% cream for nodular and
was a vehicle-controlled, 16-week, dose-ranging study (9). The histologically confirmed cure rate varied depending upon the frequency of dosing, and the overall response rate was 83% (20/24) in the imiquimod-treated group and 9% (1/11) in the vehicle treated group.